Free Trial
→ Is Elon's empire crumbling? (From Brownstone Research) (Ad) Free BMY Stock Alerts

Bristol Myers Squibb (BMY) Financials

Bristol Myers Squibb logo
$45.32 +0.50 (+1.10%)
Closing price 08/7/2025 03:59 PM Eastern
Extended Trading
$45.45 +0.14 (+0.30%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Bristol Myers Squibb

Annual Income Statements for Bristol Myers Squibb

This table shows Bristol Myers Squibb's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 2,004 1,565 4,457 1,007 4,920 3,439 -9,015 6,994 6,327 8,025 -8,948
Consolidated Net Income / (Loss)		 2,029 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933
Net Income / (Loss) Continuing Operations		 2,029 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933
Total Pre-Tax Income 		2,381 2,077 5,915 5,131 5,968 4,975 -6,871 8,098 7,713 8,440 -8,379
Total Operating Income		 2,591 1,890 4,467 3,446 5,114 5,913 -9,185 7,378 8,289 7,282 -7,486
Total Gross Profit		 11,947 12,651 14,458 14,762 16,094 18,067 30,745 35,286 35,207 33,400 20,959
Total Revenue		 15,879 16,560 19,427 20,776 22,561 26,145 42,518 46,385 46,159 45,006 48,300
Operating Revenue		 11,660 14,045 19,427 20,776 22,561 26,145 42,518 46,385 46,159 45,006 48,300
Total Cost of Revenue		 3,932 3,909 4,969 6,014 6,467 8,078 11,773 11,099 10,952 11,606 27,341
Operating Cost of Revenue		 3,932 3,909 4,969 6,014 6,467 8,078 11,773 11,099 10,952 11,606 27,341
Total Operating Expenses		 9,356 10,761 9,991 11,316 10,980 12,154 39,930 27,908 26,918 26,118 28,445
Selling, General & Admin Expense		 4,822 4,841 4,979 4,751 4,551 4,871 7,661 7,690 7,814 7,772 8,414
Research & Development Expense		 4,534 5,920 5,012 6,468 6,332 6,148 10,048 10,195 9,509 9,299 11,159
Amortization Expense		 - - - 97 97 1,135 9,688 10,023 9,595 9,047 8,872
Total Other Income / (Expense), net		 -210 187 1,448 1,685 854 -938 2,314 720 -576 1,158 -893
Other Income / (Expense), net		 -210 187 1,448 1,685 854 -938 2,314 720 -576 1,158 -893
Income Tax Expense		 352 446 1,408 4,156 1,021 1,515 2,124 1,084 1,368 400 554
Net Income / (Loss) Attributable to Noncontrolling Interest		 25 66 50 -32 27 21 20 20 18 15 15
Basic Earnings per Share		 $1.21 $0.94 $2.67 $0.61 $3.01 $2.02 ($3.99) $3.15 $2.97 $3.88 ($4.41)
Weighted Average Basic Shares Outstanding		 1.66B 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Diluted Earnings per Share		 $1.20 $0.93 $2.65 $0.61 $3.01 $2.01 ($3.99) $3.12 $2.95 $3.86 ($4.41)
Weighted Average Diluted Shares Outstanding		 1.66B 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Weighted Average Basic & Diluted Shares Outstanding		 1.66B 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Cash Dividends to Common per Share		 $1.45 $1.49 $1.53 $1.57 $1.61 $1.68 $1.84 $2.01 $2.19 $2.31 $2.42

Quarterly Income Statements for Bristol Myers Squibb

This table shows Bristol Myers Squibb's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 2,022 2,262 2,073 1,928 1,762 -11,911 1,680 1,211 72 2,456 1,310
Consolidated Net Income / (Loss)		 2,025 2,267 2,077 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313
Net Income / (Loss) Continuing Operations		 2,025 2,267 2,077 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313
Total Pre-Tax Income 		1,859 2,770 1,859 2,137 1,674 -11,516 1,286 1,676 175 2,971 1,773
Total Operating Income		 1,642 2,357 1,743 1,879 1,303 -11,435 1,559 1,910 480 3,309 2,266
Total Gross Profit		 8,761 8,696 8,192 8,380 8,132 -4,016 8,802 8,673 7,500 7,980 7,389
Total Revenue		 11,406 11,337 11,226 10,966 11,477 11,865 12,201 11,892 12,342 11,201 12,269
Operating Revenue		 11,406 11,337 11,226 10,966 11,477 11,865 12,201 11,892 12,342 11,201 12,269
Total Cost of Revenue		 2,645 2,641 3,034 2,586 3,345 15,881 3,399 3,219 4,842 3,221 4,880
Operating Cost of Revenue		 2,645 2,641 3,034 2,586 3,345 15,881 3,399 3,219 4,842 3,221 4,880
Total Operating Expenses		 7,119 6,339 6,449 6,501 6,829 7,419 7,243 6,763 7,020 4,671 5,123
Selling, General & Admin Expense		 2,266 1,762 1,934 2,003 2,073 2,367 1,928 1,983 2,136 1,584 1,713
Research & Development Expense		 2,510 2,321 2,258 2,242 2,478 2,695 2,899 2,374 3,191 2,257 2,580
Amortization Expense		 2,343 2,256 2,257 2,256 2,278 2,357 2,416 2,406 1,693 830 830
Total Other Income / (Expense), net		 217 413 116 258 371 -81 -273 -234 -305 -339 -494
Other Income / (Expense), net		 217 413 116 258 371 -81 -273 -234 -305 -339 -494
Income Tax Expense		 -166 503 -218 203 -88 392 -398 461 99 509 460
Net Income / (Loss) Attributable to Noncontrolling Interest		 3.00 5.00 4.00 6.00 - 3.00 4.00 4.00 4.00 6.00 2.00
Basic Earnings per Share		 $0.95 $1.08 $0.99 $0.94 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.21 $0.64
Weighted Average Basic Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Diluted Earnings per Share		 $0.95 $1.07 $0.99 $0.93 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.20 $0.64
Weighted Average Diluted Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Weighted Average Basic & Diluted Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Cash Dividends to Common per Share		 - $0.57 $0.57 $0.57 - $0.60 $0.60 $0.60 - $0.62 $0.62

Annual Cash Flow Statements for Bristol Myers Squibb

This table details how cash moves in and out of Bristol Myers Squibb's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1,985 -3,186 1,852 1,132 1,531 5,909 2,153 -657 -4,991 2,194 -1,172
Net Cash From Operating Activities		 3,148 2,105 3,058 5,275 7,066 8,210 14,052 16,207 13,066 13,860 15,190
Net Cash From Continuing Operating Activities		 3,148 2,105 3,058 5,275 7,066 8,210 14,052 16,207 13,066 13,860 15,190
Net Income / (Loss) Continuing Operations		 2,029 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933
Consolidated Net Income / (Loss)		 2,029 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933
Depreciation Expense		 467 376 382 789 637 1,746 10,380 10,686 10,276 9,760 9,600
Non-Cash Adjustments To Reconcile Net Income		 -19 935 -644 677 1,034 -1,453 12,454 1,703 1,412 1,262 15,802
Changes in Operating Assets and Liabilities, net		 -300 -1,082 -1,356 2,598 262 2,769 213 -3,196 -4,967 -5,202 -1,279
Net Cash From Investing Activities		 1,216 -1,572 1,480 -66 -2,000 -9,913 -10,859 -538 -1,062 -2,295 -21,352
Net Cash From Continuing Investing Activities		 1,216 -1,572 1,480 -66 -2,000 -9,913 -10,859 -538 -1,062 -2,295 -21,352
Purchase of Property, Plant & Equipment		 -526 -820 -1,215 -1,055 -951 -836 -753 -973 -1,118 -1,209 -1,248
Acquisitions		 -219 -1,111 -359 -726 -2,372 -24,777 -13,084 -1,610 -4,286 -1,169 -21,821
Purchase of Investments		 -5,719 -3,143 -3,089 -5,419 -2,305 -3,961 -4,172 -5,478 -3,592 -1,774 -769
Divestitures		 3,585 708 1,334 736 1,249 15,852 870 748 1,305 909 1,099
Sale and/or Maturity of Investments		 4,095 2,794 4,809 6,398 2,379 3,809 6,280 6,775 6,629 948 1,387
Net Cash From Financing Activities		 -2,437 -3,624 -2,653 -4,077 -3,535 7,621 -1,151 -16,224 -16,962 -9,416 5,127
Net Cash From Continuing Financing Activities		 -2,437 -3,624 -2,653 -4,077 -3,535 7,621 -1,151 -16,224 -16,962 -9,416 5,127
Repayment of Debt		 -432 -2,406 0.00 -1,246 -602 -9,178 -2,475 -5,541 -11,237 -3,999 -5,774
Repurchase of Common Equity		 0.00 0.00 -231 -2,469 -320 -7,300 -1,546 -6,287 -8,001 -5,155 0.00
Payment of Dividends		 -2,398 -2,477 -2,547 -2,577 -2,613 -2,679 -4,075 -4,396 -4,634 -4,744 -4,863
Issuance of Debt		 0.00 1,259 125 2,215 0.00 26,778 6,945 0.00 5,926 4,455 15,870
Other Financing Activities, net		 105 - - - - - - - 984 27 -106
Effect of Exchange Rate Changes		 58 -95 -33 - - -9.00 111 -102 -33 45 -137

Quarterly Cash Flow Statements for Bristol Myers Squibb

This table details how cash moves in and out of Bristol Myers Squibb's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 1,368 -277 -623 -857 3,951 -2,185 -3,038 1,597 2,454 528 1,736
Net Cash From Operating Activities		 3,306 2,970 1,887 4,751 4,252 2,834 2,326 5,591 4,439 1,954 3,917
Net Cash From Continuing Operating Activities		 3,306 2,970 1,887 4,751 4,252 2,834 2,326 5,591 4,439 1,954 3,917
Net Income / (Loss) Continuing Operations		 2,025 2,267 2,077 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313
Consolidated Net Income / (Loss)		 2,025 2,267 2,077 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313
Depreciation Expense		 2,521 2,429 2,432 2,435 2,464 2,532 2,596 2,592 1,880 1,012 1,011
Non-Cash Adjustments To Reconcile Net Income		 -158 182 164 418 498 12,723 748 333 1,998 128 1,679
Changes in Operating Assets and Liabilities, net		 -1,082 -1,908 -2,786 -36 -472 -513 -2,702 1,451 485 -1,648 -86
Net Cash From Investing Activities		 1,213 -210 -329 -410 -1,346 -19,618 -1,319 -219 -196 -499 -473
Net Cash From Continuing Investing Activities		 1,213 -210 -329 -410 -1,346 -19,618 -1,319 -219 -196 -499 -473
Purchase of Property, Plant & Equipment		 -346 -278 -259 -342 -330 -284 -262 -324 -378 -260 -361
Acquisitions		 -116 -78 -184 -326 -581 -20,053 -1,373 -348 -47 -78 -285
Purchase of Investments		 -26 -200 -355 -502 -717 -274 -84 -40 -371 -636 -621
Divestitures		 490 227 194 247 241 241 270 255 333 243 270
Sale and/or Maturity of Investments		 1,211 119 275 513 41 752 130 238 267 232 524
Net Cash From Financing Activities		 -3,246 -3,050 -2,173 -5,160 967 14,644 -4,023 -3,852 -1,642 -993 -1,836
Net Cash From Continuing Financing Activities		 -3,246 -3,050 -2,173 -5,160 967 14,644 -4,023 -3,852 -1,642 -993 -1,836
Repayment of Debt		 136 -1,512 -124 -10 -2,353 83 -5,787 -2,652 -405 368 -585
Payment of Dividends		 -1,145 -1,196 -1,197 -1,191 -1,160 -1,212 -1,217 -1,216 -1,218 -1,258 -1,262
Other Financing Activities, net		 179 -92 53 41 25 -97 -6.00 16 -19 -103 11
Effect of Exchange Rate Changes		 95 13 -8.00 -38 78 -45 -22 77 -147 66 128

Annual Balance Sheets for Bristol Myers Squibb

This table presents Bristol Myers Squibb's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 33,749 31,748 33,707 33,551 34,986 129,944 118,481 109,314 96,820 95,159 92,603
Total Current Assets		 14,608 10,415 13,704 14,854 17,716 29,354 30,192 33,262 27,273 31,770 29,780
Cash & Equivalents		 5,571 2,385 4,237 5,421 6,911 12,346 14,546 13,979 9,123 11,464 10,346
Short-Term Investments		 1,864 1,885 2,113 1,391 1,848 3,047 1,285 2,987 130 816 513
Accounts Receivable		 3,390 4,299 5,543 6,300 5,747 7,685 8,501 9,369 9,886 10,921 10,747
Inventories, net		 1,560 1,221 1,241 1,166 1,195 4,293 2,074 2,095 2,339 2,662 2,557
Other Current Assets		 579 625 570 576 2,015 1,983 3,786 4,832 5,795 5,907 5,617
Plant, Property, & Equipment, net		 4,417 4,412 4,980 5,001 5,027 6,252 5,886 6,049 6,255 6,646 7,136
Total Noncurrent Assets		 14,724 16,921 15,023 13,696 12,243 94,338 82,403 70,003 63,292 56,743 55,687
Long-Term Investments		 4,408 4,660 2,719 2,480 1,775 767 433 - 0.00 364 320
Goodwill		 7,027 6,881 6,875 6,863 6,538 22,488 20,547 20,502 21,149 21,169 21,719
Intangible Assets		 1,753 1,419 1,385 1,210 1,091 63,969 53,243 42,527 35,859 27,072 23,307
Noncurrent Deferred & Refundable Income Taxes		 915 2,844 2,996 1,610 815 510 1,161 1,439 1,344 2,768 4,236
Other Noncurrent Operating Assets		 621 1,117 1,048 1,533 2,024 6,604 7,019 5,535 4,940 5,370 6,105
Total Liabilities & Shareholders' Equity		 33,749 31,748 33,707 33,551 34,986 129,944 118,481 109,314 96,820 95,159 92,603
Total Liabilities		 18,766 17,324 17,360 21,704 20,859 78,246 80,599 73,308 65,702 65,674 76,215
Total Current Liabilities		 8,461 8,017 8,841 9,563 10,654 18,304 19,080 21,868 21,890 22,262 23,774
Short-Term Debt		 590 139 992 987 1,703 3,346 2,340 4,948 4,264 3,119 2,046
Accounts Payable		 2,487 1,565 1,664 2,248 1,892 2,445 2,713 2,949 3,040 3,259 3,602
Other Current Liabilities		 - - - - 7,059 12,513 14,027 13,971 14,586 15,884 18,126
Total Noncurrent Liabilities		 10,305 9,307 8,519 12,141 10,205 59,942 61,519 51,440 43,812 43,412 52,441
Long-Term Debt		 7,242 6,550 5,716 6,975 5,646 43,387 48,336 39,605 35,056 36,653 47,603
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 19 6,454 5,407 4,501 2,166 338 369
Other Noncurrent Operating Liabilities		 618 1,429 1,283 1,164 4,540 10,101 7,776 7,334 6,590 6,421 4,469
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14,983 14,424 16,347 11,847 14,127 51,698 37,882 36,006 31,118 29,485 16,388
Total Preferred & Common Equity		 14,852 14,266 16,177 11,741 14,031 51,598 37,822 35,946 31,061 29,430 16,335
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 14,852 14,266 16,177 11,741 14,031 51,598 37,822 35,946 31,061 29,430 16,335
Common Stock		 1,728 1,680 1,946 2,119 2,302 44,001 44,617 44,653 45,457 45,976 46,316
Retained Earnings		 32,541 31,613 33,513 31,160 34,065 34,474 21,281 23,820 25,503 28,766 14,912
Treasury Stock		 -16,992 -16,559 -16,779 -19,249 -19,574 -25,357 -26,237 -31,259 -38,618 -43,766 -43,655
Accumulated Other Comprehensive Income / (Loss)		 -2,425 -2,468 -2,503 -2,289 -2,762 -1,520 -1,839 -1,268 -1,281 -1,546 -1,238
Noncontrolling Interest		 131 158 170 106 96 100 60 60 57 55 53

Quarterly Balance Sheets for Bristol Myers Squibb

This table presents Bristol Myers Squibb's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Total Assets		 96,820 94,281 93,489 91,263 95,159 99,031 94,646 93,670 92,603 92,427 94,676
Total Current Assets		 27,273 27,086 28,074 27,632 31,770 28,669 26,890 28,075 29,780 30,783 33,222
Cash & Equivalents		 9,123 8,995 8,372 7,514 11,464 9,330 6,293 7,890 10,346 10,875 12,599
Short-Term Investments		 130 274 358 171 816 340 360 204 513 907 1,004
Accounts Receivable		 9,886 10,054 10,112 10,304 10,921 10,447 11,423 11,026 10,747 10,801 11,415
Inventories, net		 2,339 2,605 2,364 2,436 2,662 2,985 3,077 3,332 2,557 2,666 2,737
Other Current Assets		 5,795 5,158 6,868 7,207 5,907 5,567 5,737 5,623 5,617 5,534 5,466
Plant, Property, & Equipment, net		 6,255 6,279 6,355 6,481 6,646 6,750 6,845 6,903 7,136 7,213 7,373
Total Noncurrent Assets		 63,292 60,916 59,060 56,825 56,743 63,612 60,911 58,692 55,687 54,430 54,083
Long-Term Investments		 0.00 - - - 364 367 357 324 320 344 346
Goodwill		 21,149 21,162 21,163 21,147 21,169 21,738 21,732 21,751 21,719 21,737 21,776
Intangible Assets		 35,859 33,569 31,303 28,950 27,072 32,760 29,428 26,964 23,307 22,486 21,378
Noncurrent Deferred & Refundable Income Taxes		 1,344 1,317 1,572 1,514 2,768 2,723 3,323 3,609 4,236 3,997 4,647
Other Noncurrent Operating Assets		 4,940 4,868 5,022 5,214 5,370 6,024 6,071 6,044 6,105 5,866 5,936
Total Liabilities & Shareholders' Equity		 96,820 94,281 93,489 91,263 95,159 99,031 94,646 93,670 92,603 92,427 94,676
Total Liabilities		 65,702 62,395 61,459 62,201 65,674 82,483 77,577 76,470 76,215 74,979 77,187
Total Current Liabilities		 21,890 19,085 20,150 23,462 22,262 25,822 23,265 22,638 23,774 24,070 27,528
Short-Term Debt		 4,264 2,752 3,020 5,467 3,119 6,190 3,531 1,078 2,046 3,554 4,715
Accounts Payable		 3,040 3,194 3,069 2,813 3,259 3,539 3,751 3,469 3,602 4,002 5,427
Other Current Liabilities		 14,586 13,139 14,061 15,182 15,884 16,093 15,983 18,091 18,126 16,514 17,386
Total Noncurrent Liabilities		 43,812 43,310 41,309 38,739 43,412 56,661 54,312 53,832 52,441 50,910 49,659
Long-Term Debt		 35,056 35,078 34,656 32,137 36,653 49,487 48,858 48,674 47,603 46,157 44,470
Noncurrent Deferred & Payable Income Tax Liabilities		 2,166 1,568 751 399 338 442 461 430 369 276 247
Other Noncurrent Operating Liabilities		 6,590 6,664 5,902 6,203 6,421 6,732 4,993 4,728 4,469 4,477 4,942
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 31,118 31,886 32,030 29,062 29,485 16,548 17,069 17,200 16,388 17,448 17,489
Total Preferred & Common Equity		 31,061 31,824 31,973 28,998 29,430 16,490 17,015 17,142 16,335 17,389 17,435
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 31,061 31,824 31,973 28,998 29,430 16,490 17,015 17,142 16,335 17,388 17,436
Common Stock		 45,457 45,432 45,591 45,141 45,976 45,947 46,058 46,188 46,316 46,303 46,426
Retained Earnings		 25,503 26,568 27,449 28,218 28,766 15,640 16,103 16,097 14,912 16,106 16,154
Treasury Stock		 -38,618 -38,808 -39,680 -43,075 -43,766 -43,697 -43,690 -43,675 -43,655 -43,597 -43,590
Accumulated Other Comprehensive Income / (Loss)		 -1,281 -1,368 -1,387 -1,286 -1,546 -1,400 -1,456 -1,468 -1,238 -1,424 -1,554
Noncontrolling Interest		 57 62 57 64 55 58 54 58 53 59 54

Annual Metrics And Ratios for Bristol Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol Myers Squibb's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -3.09% 4.29% 17.31% 6.94% 8.59% 15.89% 62.62% 9.10% -0.49% -2.50% 7.32%
EBITDA Growth		 -3.27% -29.35% 139.66% -4.79% 10.32% 23.83% -58.27% 435.31% -4.23% 1.17% -93.29%
EBIT Growth		 -17.64% -12.77% 184.79% -13.25% 16.31% -16.64% -238.11% 217.86% -4.75% 9.43% -199.28%
NOPAT Growth		 -20.09% -32.78% 129.33% -80.76% 547.38% -2.99% -256.35% 199.39% 6.70% 1.73% -175.54%
Net Income Growth		 -21.36% -19.62% 176.33% -78.37% 407.38% -30.06% -359.97% 177.98% -9.54% 26.71% -211.11%
EPS Growth		 -22.08% -22.50% 184.95% -76.98% 393.44% -33.22% -298.51% 178.20% -5.45% 30.85% -214.25%
Operating Cash Flow Growth		 -11.20% -33.13% 45.27% 72.50% 33.95% 16.19% 71.16% 15.34% -19.38% 6.08% 9.60%
Free Cash Flow Firm Growth		 -12.17% -77.27% 74.34% 157.63% -7.51% -1,862.32% 105.28% 325.41% -38.86% 24.73% -130.28%
Invested Capital Growth		 -13.62% 4.87% 14.80% -24.80% 4.04% 651.88% -12.13% -12.04% -3.79% -7.47% -3.10%
Revenue Q/Q Growth		 -1.14% 0.18% 5.18% 1.00% 2.38% 8.16% 7.93% 2.02% -1.24% 0.16% 1.82%
EBITDA Q/Q Growth		 -0.93% -28.49% 30.78% -4.23% 12.14% -6.72% -71.74% 184.95% -0.28% -1.31% -63.04%
EBIT Q/Q Growth		 -28.07% -14.42% 33.85% -7.03% 15.64% -24.72% -299.10% 292.58% 0.09% -2.14% -21.79%
NOPAT Q/Q Growth		 -2.58% -28.02% 23.88% -77.20% 269.00% -30.79% -21,598.68% 227.79% -11.63% -5.45% -12.35%
Net Income Q/Q Growth		 -25.87% -11.65% 31.75% -76.80% 238.84% -39.06% -32,025.00% 230.25% -5.19% -3.17% -23.26%
EPS Q/Q Growth		 -25.93% -12.26% 32.50% -75.98% 234.44% -41.74% -1,275.86% 231.09% -3.91% -2.03% -22.84%
Operating Cash Flow Q/Q Growth		 -21.02% 17.40% 22.37% -5.82% 52.68% -14.34% 9.12% 4.53% -5.44% 7.33% 1.25%
Free Cash Flow Firm Q/Q Growth		 -37.99% 6.51% -14.79% 29.89% 44.05% -854.76% 105.52% 582.50% -17.82% 0.20% 23.27%
Invested Capital Q/Q Growth		 -2.73% -7.30% -0.19% -23.28% -10.38% 789.80% -1.68% -4.11% -2.58% -3.48% -6.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.24% 76.39% 74.42% 71.05% 71.34% 69.10% 72.31% 76.07% 76.27% 74.21% 43.39%
EBITDA Margin		 24.05% 16.29% 33.28% 29.63% 30.10% 32.16% 8.25% 40.50% 38.97% 40.44% 2.53%
Operating Margin		 16.32% 11.41% 22.99% 16.59% 22.67% 22.62% -21.60% 15.91% 17.96% 16.18% -15.50%
EBIT Margin		 14.99% 12.54% 30.45% 24.70% 26.45% 19.03% -16.16% 17.46% 16.71% 18.75% -17.35%
Profit (Net Income) Margin		 12.78% 9.85% 23.20% 4.69% 21.93% 13.23% -21.16% 15.12% 13.75% 17.86% -18.49%
Tax Burden Percent		 85.22% 78.53% 76.20% 19.00% 82.89% 69.55% 130.91% 86.61% 82.26% 95.26% 106.61%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 14.78% 21.47% 23.80% 81.00% 17.11% 30.45% 0.00% 13.39% 17.74% 4.74% 0.00%
Return on Invested Capital (ROIC)		 17.62% 12.47% 26.01% 5.34% 39.51% 8.82% -8.32% 9.41% 10.93% 11.78% -9.40%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.56% 7.23% -21.94% -12.00% 8.15% 4.06% -16.22% 11.42% 9.29% 15.64% -20.66%
Return on Net Nonoperating Assets (RNNOA)		 -4.19% -1.38% 3.28% 1.57% -1.42% 1.69% -11.76% 9.58% 7.98% 14.76% -29.54%
Return on Equity (ROE)		 13.43% 11.09% 29.29% 6.92% 38.09% 10.51% -20.08% 18.99% 18.91% 26.53% -38.95%
Cash Return on Invested Capital (CROIC)		 32.23% 7.72% 12.23% 33.66% 35.55% -144.22% 4.59% 22.21% 14.79% 19.54% -6.25%
Operating Return on Assets (OROA)		 6.58% 6.34% 18.07% 15.26% 17.42% 6.03% -5.53% 7.11% 7.48% 8.79% -8.93%
Return on Assets (ROA)		 5.61% 4.98% 13.77% 2.90% 14.44% 4.20% -7.24% 6.16% 6.16% 8.38% -9.52%
Return on Common Equity (ROCE)		 13.33% 10.98% 28.98% 6.85% 37.80% 10.48% -20.05% 18.95% 18.87% 26.48% -38.86%
Return on Equity Simple (ROE_SIMPLE)		 13.66% 11.43% 27.86% 8.30% 35.26% 6.71% -23.78% 19.51% 20.43% 27.32% -54.69%
Net Operating Profit after Tax (NOPAT)		 2,208 1,484 3,404 655 4,239 4,112 -6,430 6,390 6,819 6,937 -5,240
NOPAT Margin		 13.90% 8.96% 17.52% 3.15% 18.79% 15.73% -15.12% 13.78% 14.77% 15.41% -10.85%
Net Nonoperating Expense Percent (NNEP)		 -6.95% 5.24% 47.95% 17.35% 31.36% 4.76% 7.90% -2.01% 1.64% -3.86% 11.26%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 9.68% 10.02% -7.94%
Cost of Revenue to Revenue		 24.76% 23.61% 25.58% 28.95% 28.66% 30.90% 27.69% 23.93% 23.73% 25.79% 56.61%
SG&A Expenses to Revenue		 30.37% 29.23% 25.63% 22.87% 20.17% 18.63% 18.02% 16.58% 16.93% 17.27% 17.42%
R&D to Revenue		 28.55% 35.75% 25.80% 31.13% 28.07% 23.52% 23.63% 21.98% 20.60% 20.66% 23.10%
Operating Expenses to Revenue		 58.92% 64.98% 51.43% 54.47% 48.67% 46.49% 93.91% 60.17% 58.32% 58.03% 58.89%
Earnings before Interest and Taxes (EBIT)		 2,381 2,077 5,915 5,131 5,968 4,975 -6,871 8,098 7,713 8,440 -8,379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3,819 2,698 6,466 6,156 6,791 8,409 3,509 18,784 17,989 18,200 1,221
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.05 6.30 4.82 7.00 5.09 1.76 3.35 3.56 4.48 3.34 6.95
Price to Tangible Book Value (P/TBV)		 12.35 15.07 9.84 22.41 11.15 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.72 5.43 4.01 3.96 3.16 3.48 2.98 2.76 3.01 2.18 2.35
Price to Earnings (P/E)		 37.41 57.45 17.48 81.62 14.51 26.47 0.00 18.32 21.98 12.25 0.00
Dividend Yield		 3.21% 2.76% 3.26% 3.11% 3.66% 2.94% 3.28% 3.40% 3.30% 4.72% 4.29%
Earnings Yield		 2.67% 1.74% 5.72% 1.23% 6.89% 3.78% 0.00% 5.46% 4.55% 8.16% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.12 7.21 5.41 7.70 6.24 1.48 2.23 2.45 2.77 2.22 2.77
Enterprise Value to Revenue (EV/Rev)		 4.48 5.30 3.90 3.90 3.03 4.66 3.79 3.36 3.67 2.79 3.15
Enterprise Value to EBITDA (EV/EBITDA)		 18.61 32.55 11.71 13.15 10.06 14.47 45.95 8.29 9.41 6.89 124.48
Enterprise Value to EBIT (EV/EBIT)		 29.86 42.29 12.80 15.78 11.45 24.46 0.00 19.24 21.94 14.87 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 32.20 59.18 22.25 123.65 16.11 29.60 0.00 24.38 24.81 18.09 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 22.58 41.72 24.76 15.35 9.67 14.82 11.48 9.61 12.95 9.05 10.01
Enterprise Value to Free Cash Flow (EV/FCFF)		 17.60 95.66 47.31 19.63 17.91 0.00 45.46 10.32 18.34 10.90 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.52 0.46 0.41 0.67 0.52 0.90 1.34 1.24 1.26 1.35 3.03
Long-Term Debt to Equity		 0.48 0.45 0.35 0.59 0.40 0.84 1.28 1.10 1.13 1.24 2.90
Financial Leverage		 -0.17 -0.19 -0.15 -0.13 -0.17 0.42 0.73 0.84 0.86 0.94 1.43
Leverage Ratio		 2.39 2.23 2.13 2.39 2.64 2.51 2.77 3.08 3.07 3.17 4.09
Compound Leverage Factor		 2.39 2.23 2.13 2.39 2.64 2.51 2.77 3.08 3.07 3.17 4.09
Debt to Total Capital		 34.33% 31.68% 29.10% 40.19% 34.22% 47.48% 57.22% 55.30% 55.82% 57.43% 75.18%
Short-Term Debt to Total Capital		 2.59% 0.66% 4.30% 4.98% 7.93% 3.40% 2.64% 6.14% 6.05% 4.50% 3.10%
Long-Term Debt to Total Capital		 31.74% 31.02% 24.79% 35.21% 26.29% 44.08% 54.58% 49.16% 49.77% 52.92% 72.09%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.57% 0.75% 0.74% 0.54% 0.45% 0.10% 0.07% 0.07% 0.08% 0.08% 0.08%
Common Equity to Total Capital		 65.10% 67.57% 70.17% 59.27% 65.33% 52.42% 42.71% 44.62% 44.10% 42.49% 24.74%
Debt to EBITDA		 2.05 2.48 1.04 1.29 1.08 5.56 14.44 2.37 2.19 2.19 40.66
Net Debt to EBITDA		 -1.05 -0.83 -0.37 -0.22 -0.47 3.64 9.81 1.47 1.67 1.49 31.51
Long-Term Debt to EBITDA		 1.90 2.43 0.88 1.13 0.83 5.16 13.77 2.11 1.95 2.01 38.99
Debt to NOPAT		 3.55 4.51 1.97 12.16 1.73 11.36 -7.88 6.97 5.77 5.73 -9.47
Net Debt to NOPAT		 -1.82 -1.51 -0.69 -2.03 -0.75 7.43 -5.35 4.32 4.41 3.91 -7.34
Long-Term Debt to NOPAT		 3.28 4.41 1.68 10.65 1.33 10.55 -7.52 6.20 5.14 5.28 -9.08
Altman Z-Score		 4.67 5.34 5.41 4.89 4.87 1.50 1.48 2.15 2.45 2.21 1.42
Noncontrolling Interest Sharing Ratio		 0.70% 0.98% 1.07% 0.98% 0.78% 0.30% 0.18% 0.16% 0.17% 0.18% 0.24%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.73 1.30 1.55 1.55 1.66 1.60 1.58 1.52 1.25 1.43 1.25
Quick Ratio		 1.28 1.07 1.35 1.37 1.36 1.26 1.28 1.20 0.87 1.04 0.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4,040 918 1,601 4,124 3,814 -67,217 3,548 15,091 9,227 11,509 -3,485
Operating Cash Flow to CapEx		 598.48% 256.71% 251.69% 500.00% 743.01% 982.06% 1,866.14% 1,665.67% 1,168.69% 1,146.40% 1,217.15%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.44 0.51 0.59 0.62 0.66 0.32 0.34 0.41 0.45 0.47 0.51
Accounts Receivable Turnover		 4.70 4.31 3.95 3.51 3.75 3.89 5.25 5.19 4.79 4.33 4.46
Inventory Turnover		 2.57 2.81 4.04 5.00 5.48 2.94 3.70 5.32 4.94 4.64 10.48
Fixed Asset Turnover		 3.53 3.75 4.14 4.16 4.50 4.64 7.01 7.77 7.50 6.98 7.01
Accounts Payable Turnover		 1.56 1.93 3.08 3.07 3.12 3.73 4.56 3.92 3.66 3.69 7.97
Days Sales Outstanding (DSO)		 77.58 84.74 92.46 104.03 97.45 93.76 69.48 70.31 76.13 84.37 81.87
Days Inventory Outstanding (DIO)		 141.93 129.84 90.42 73.04 66.63 123.99 98.70 68.55 73.89 78.64 34.84
Days Payable Outstanding (DPO)		 234.21 189.18 118.59 118.71 116.83 97.98 79.96 93.10 99.80 99.05 45.80
Cash Conversion Cycle (CCC)		 -14.69 25.40 64.29 58.36 47.25 119.76 88.22 45.76 50.22 63.96 70.91
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11,617 12,183 13,986 10,517 10,942 82,271 72,294 63,593 61,185 56,613 54,858
Invested Capital Turnover		 1.27 1.39 1.48 1.70 2.10 0.56 0.55 0.68 0.74 0.76 0.87
Increase / (Decrease) in Invested Capital		 -1,832 566 1,803 -3,469 425 71,329 -9,977 -8,701 -2,408 -4,572 -1,755
Enterprise Value (EV)		 71,086 87,831 75,730 80,969 68,308 121,711 161,256 155,767 169,192 125,477 151,984
Market Capitalization		 74,966 89,914 77,921 82,193 71,397 91,038 126,784 128,120 139,068 98,294 113,461
Book Value per Share		 $8.95 $8.55 $9.68 $7.17 $8.60 $31.67 $16.74 $16.19 $14.61 $14.46 $8.05
Tangible Book Value per Share		 $3.66 $3.58 $4.74 $2.24 $3.92 ($21.40) ($15.92) ($12.20) ($12.20) ($9.24) ($14.15)
Total Capital		 22,815 21,113 23,055 19,809 21,476 98,431 88,558 80,559 70,438 69,257 66,037
Total Debt		 7,832 6,689 6,708 7,962 7,349 46,733 50,676 44,553 39,320 39,772 49,649
Total Long-Term Debt		 7,242 6,550 5,716 6,975 5,646 43,387 48,336 39,605 35,056 36,653 47,603
Net Debt		 -4,011 -2,241 -2,361 -1,330 -3,185 30,573 34,412 27,587 30,067 27,128 38,470
Capital Expenditures (CapEx)		 526 820 1,215 1,055 951 836 753 973 1,118 1,209 1,248
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -698 -1,733 -495 -534 6.00 -997 -2,379 -624 394 347 -2,807
Debt-free Net Working Capital (DFNWC)		 6,737 2,537 5,855 6,278 8,765 14,396 13,452 16,342 9,647 12,627 8,052
Net Working Capital (NWC)		 6,147 2,398 4,863 5,291 7,062 11,050 11,112 11,394 5,383 9,508 6,006
Net Nonoperating Expense (NNE)		 179 -147 -1,103 -320 -708 652 2,566 -624 474 -1,103 3,693
Net Nonoperating Obligations (NNO)		 -3,366 -2,241 -2,361 -1,330 -3,185 30,573 34,412 27,587 30,067 27,128 38,470
Total Depreciation and Amortization (D&A)		 1,438 621 551 1,025 823 3,434 10,380 10,686 10,276 9,760 9,600
Debt-free, Cash-free Net Working Capital to Revenue		 -4.40% -10.47% -2.55% -2.57% 0.03% -3.81% -5.60% -1.35% 0.85% 0.77% -5.81%
Debt-free Net Working Capital to Revenue		 42.43% 15.32% 30.14% 30.22% 38.85% 55.06% 31.64% 35.23% 20.90% 28.06% 16.67%
Net Working Capital to Revenue		 38.71% 14.48% 25.03% 25.47% 31.30% 42.26% 26.13% 24.56% 11.66% 21.13% 12.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.21 $0.94 $2.67 $0.61 $3.01 $2.02 ($3.99) $3.15 $2.97 $3.88 ($4.41)
Adjusted Weighted Average Basic Shares Outstanding		 1.66B 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Adjusted Diluted Earnings per Share		 $1.20 $0.93 $2.65 $0.61 $3.01 $2.01 ($3.99) $3.12 $2.95 $3.86 ($4.41)
Adjusted Weighted Average Diluted Shares Outstanding		 1.66B 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $2.02 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.66B 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B
Normalized Net Operating Profit after Tax (NOPAT)		 2,208 1,484 3,404 2,412 4,239 4,112 -6,430 6,390 6,819 6,937 -5,240
Normalized NOPAT Margin		 13.90% 8.96% 17.52% 11.61% 18.79% 15.73% -15.12% 13.78% 14.77% 15.41% -10.85%
Pre Tax Income Margin		 14.99% 12.54% 30.45% 24.70% 26.45% 19.03% -16.16% 17.46% 16.71% 18.75% -17.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 118.19% 151.87% 56.51% 264.31% 52.82% 77.43% -45.30% 62.67% 73.03% 59.01% -54.44%
Augmented Payout Ratio		 118.19% 151.87% 61.64% 517.54% 59.29% 288.41% -62.49% 152.31% 199.13% 123.12% -54.44%

Quarterly Metrics And Ratios for Bristol Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol Myers Squibb's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.83% -2.67% -5.56% -2.25% 0.62% 4.66% 8.69% 8.44% 7.54% -5.60% 0.56%
EBITDA Growth		 -1.15% 21.73% -5.51% -4.69% -5.53% -272.80% -9.53% -6.65% -50.34% 144.32% -28.31%
EBIT Growth		 0.38% 64.20% -5.06% -3.26% -9.95% -515.74% -30.82% -21.57% -89.55% 125.79% 37.79%
NOPAT Growth		 -37.59% 8.58% 19.01% 12.91% -23.32% -514.96% 4.83% -18.58% -84.80% 134.26% -17.80%
Net Income Growth		 -14.63% 76.70% 45.35% 20.27% -12.99% -625.28% -18.92% -37.18% -95.69% 120.68% -22.03%
EPS Growth		 -11.22% 81.36% 50.00% 24.00% -8.42% -650.47% -16.16% -35.48% -94.25% 120.37% -22.89%
Operating Cash Flow Growth		 -18.51% -22.09% -16.54% 28.86% 28.61% -4.58% 23.26% 17.68% 4.40% -31.05% 68.40%
Free Cash Flow Firm Growth		 -63.72% -71.18% -72.81% 16.57% 41.63% -411.26% -76.89% -74.24% -66.96% 201.58% 1,901.81%
Invested Capital Growth		 -3.79% -1.95% -0.84% -6.61% -7.47% 2.88% 2.41% -0.21% -3.10% -11.51% -15.57%
Revenue Q/Q Growth		 1.68% -0.60% -0.98% -2.32% 4.66% 3.38% 2.83% -2.53% 3.78% -9.24% 9.53%
EBITDA Q/Q Growth		 -8.69% 18.70% -17.46% 6.55% -9.49% -317.11% 143.21% 9.94% -51.85% 93.77% -30.11%
EBIT Q/Q Growth		 -15.84% 49.00% -32.89% 14.95% -21.67% -787.93% 111.17% 30.33% -89.56% 1,597.14% -40.34%
NOPAT Q/Q Growth		 18.76% 7.85% 0.95% -12.68% -19.35% -683.63% 125.50% -32.18% -84.95% 1,215.42% -38.80%
Net Income Q/Q Growth		 25.93% 11.95% -8.38% -6.88% -8.89% -775.82% 114.14% -27.85% -93.74% 3,139.47% -46.67%
EPS Q/Q Growth		 26.67% 12.63% -7.48% -6.06% -6.45% -777.01% 114.09% -27.71% -91.67% 2,300.00% -46.67%
Operating Cash Flow Q/Q Growth		 -10.33% -10.16% -36.46% 151.78% -10.50% -33.35% -17.93% 140.37% -20.60% -55.98% 100.46%
Free Cash Flow Firm Q/Q Growth		 -16.37% -25.39% -21.29% 137.36% 1.61% -263.97% 105.84% 164.56% 30.32% 404.17% 15.16%
Invested Capital Q/Q Growth		 -2.58% -1.21% 0.88% -3.80% -3.48% 9.85% 0.42% -6.27% -6.28% 0.32% -4.19%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.81% 76.70% 72.97% 76.42% 70.85% -33.85% 72.14% 72.93% 60.77% 71.24% 60.23%
EBITDA Margin		 38.40% 45.86% 38.22% 41.69% 36.05% -75.72% 31.82% 35.89% 16.65% 35.55% 22.68%
Operating Margin		 14.40% 20.79% 15.53% 17.13% 11.35% -96.38% 12.78% 16.06% 3.89% 29.54% 18.47%
EBIT Margin		 16.30% 24.43% 16.56% 19.49% 14.59% -97.06% 10.54% 14.09% 1.42% 26.52% 14.44%
Profit (Net Income) Margin		 17.75% 20.00% 18.50% 17.64% 15.35% -100.36% 13.80% 10.22% 0.62% 21.98% 10.70%
Tax Burden Percent		 108.93% 81.84% 111.73% 90.50% 105.26% 103.40% 130.95% 72.49% 43.43% 82.87% 74.06%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.03% 100.06%
Effective Tax Rate		 -8.93% 18.16% -11.73% 9.50% -5.26% 0.00% -30.95% 27.51% 56.57% 17.13% 25.94%
Return on Invested Capital (ROIC)		 11.60% 12.78% 12.80% 11.47% 9.13% -50.10% 12.61% 9.43% 1.46% 19.90% 11.33%
ROIC Less NNEP Spread (ROIC-NNEP)		 12.42% 13.93% 13.25% 12.26% 10.50% -60.62% 11.65% 8.95% 1.06% 19.22% 10.42%
Return on Net Nonoperating Assets (RNNOA)		 10.67% 12.84% 11.83% 11.83% 9.91% -92.87% 17.63% 13.72% 1.52% 47.06% 24.32%
Return on Equity (ROE)		 22.27% 25.62% 24.63% 23.31% 19.04% -142.97% 30.24% 23.14% 2.98% 66.96% 35.65%
Cash Return on Invested Capital (CROIC)		 14.79% 13.31% 12.54% 18.91% 19.54% -10.27% -9.98% -7.75% -6.25% 23.23% 27.51%
Operating Return on Assets (OROA)		 7.30% 11.35% 7.72% 9.24% 6.84% -45.72% 5.21% 7.23% 0.73% 13.19% 7.28%
Return on Assets (ROA)		 7.95% 9.29% 8.63% 8.37% 7.20% -47.28% 6.82% 5.24% 0.32% 10.94% 5.39%
Return on Common Equity (ROCE)		 22.23% 25.57% 24.59% 23.26% 19.00% -142.61% 30.17% 23.08% 2.97% 66.73% 35.54%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 23.03% 24.95% 28.63% 0.00% -37.20% -38.37% -42.28% 0.00% 31.27% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,789 1,929 1,947 1,701 1,371 -8,005 2,041 1,385 208 2,742 1,678
NOPAT Margin		 15.68% 17.02% 17.35% 15.51% 11.95% -67.46% 16.73% 11.64% 1.69% 24.48% 13.68%
Net Nonoperating Expense Percent (NNEP)		 -0.82% -1.15% -0.45% -0.78% -1.37% 10.52% 0.96% 0.48% 0.40% 0.67% 0.91%
Return On Investment Capital (ROIC_SIMPLE)		 2.54% - - - 1.98% - - - 0.32% 4.08% 2.52%
Cost of Revenue to Revenue		 23.19% 23.30% 27.03% 23.58% 29.15% 133.85% 27.86% 27.07% 39.23% 28.76% 39.78%
SG&A Expenses to Revenue		 19.87% 15.54% 17.23% 18.27% 18.06% 19.95% 15.80% 16.68% 17.31% 14.14% 13.96%
R&D to Revenue		 22.01% 20.47% 20.11% 20.45% 21.59% 22.71% 23.76% 19.96% 25.85% 20.15% 21.03%
Operating Expenses to Revenue		 62.41% 55.91% 57.45% 59.28% 59.50% 62.53% 59.36% 56.87% 56.88% 41.70% 41.76%
Earnings before Interest and Taxes (EBIT)		 1,859 2,770 1,859 2,137 1,674 -11,516 1,286 1,676 175 2,970 1,772
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4,380 5,199 4,291 4,572 4,138 -8,984 3,882 4,268 2,055 3,982 2,783
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.48 4.35 3.97 3.94 3.34 6.61 4.87 6.05 6.95 7.04 5.33
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.01 3.02 2.81 2.54 2.18 2.40 1.78 2.19 2.35 2.57 1.95
Price to Earnings (P/E)		 21.98 18.92 15.93 13.79 12.25 0.00 0.00 0.00 0.00 22.59 18.42
Dividend Yield		 3.30% 3.32% 3.68% 4.11% 4.72% 4.31% 5.72% 4.63% 4.29% 4.01% 5.34%
Earnings Yield		 4.55% 5.28% 6.28% 7.25% 8.16% 0.00% 0.00% 0.00% 0.00% 4.43% 5.43%
Enterprise Value to Invested Capital (EV/IC)		 2.77 2.76 2.56 2.46 2.22 2.49 2.06 2.48 2.77 2.91 2.43
Enterprise Value to Revenue (EV/Rev)		 3.67 3.64 3.45 3.21 2.79 3.40 2.76 3.06 3.15 3.36 2.69
Enterprise Value to EBITDA (EV/EBITDA)		 9.41 8.83 8.35 7.82 6.89 38.53 35.58 43.93 124.48 11.28 9.80
Enterprise Value to EBIT (EV/EBIT)		 21.94 18.98 17.92 16.72 14.87 0.00 0.00 0.00 0.00 26.21 19.46
Enterprise Value to NOPAT (EV/NOPAT)		 24.81 24.11 21.76 19.66 18.09 0.00 0.00 0.00 0.00 24.78 20.96
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.95 13.66 13.16 11.17 9.05 11.28 9.06 9.67 10.01 11.19 8.07
Enterprise Value to Free Cash Flow (EV/FCFF)		 18.34 20.55 20.29 12.56 10.90 0.00 0.00 0.00 0.00 11.76 8.10
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.26 1.19 1.18 1.29 1.35 3.36 3.07 2.89 3.03 2.85 2.81
Long-Term Debt to Equity		 1.13 1.10 1.08 1.11 1.24 2.99 2.86 2.83 2.90 2.65 2.54
Financial Leverage		 0.86 0.92 0.89 0.97 0.94 1.53 1.51 1.53 1.43 2.45 2.33
Leverage Ratio		 3.07 3.11 3.00 3.07 3.17 3.99 3.83 4.00 4.09 5.63 5.48
Compound Leverage Factor		 3.07 3.11 3.00 3.07 3.17 3.99 3.83 4.00 4.09 5.63 5.48
Debt to Total Capital		 55.82% 54.26% 54.05% 56.41% 57.43% 77.09% 75.43% 74.31% 75.18% 74.02% 73.77%
Short-Term Debt to Total Capital		 6.05% 3.95% 4.33% 8.20% 4.50% 8.57% 5.08% 1.61% 3.10% 5.29% 7.07%
Long-Term Debt to Total Capital		 49.77% 50.32% 49.72% 48.21% 52.92% 68.52% 70.34% 72.70% 72.09% 68.73% 66.70%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.08% 0.09% 0.08% 0.10% 0.08% 0.08% 0.08% 0.09% 0.08% 0.09% 0.08%
Common Equity to Total Capital		 44.10% 45.65% 45.87% 43.50% 42.49% 22.83% 24.50% 25.60% 24.74% 25.89% 26.15%
Debt to EBITDA		 2.19 2.00 2.02 2.04 2.19 13.86 14.52 15.06 40.66 3.50 3.76
Net Debt to EBITDA		 1.67 1.51 1.55 1.62 1.49 11.36 12.58 12.51 31.51 2.65 2.69
Long-Term Debt to EBITDA		 1.95 1.85 1.86 1.74 2.01 12.32 13.54 14.73 38.99 3.25 3.40
Debt to NOPAT		 5.77 5.46 5.26 5.13 5.73 -12.22 -11.18 -10.67 -9.47 7.69 8.04
Net Debt to NOPAT		 4.41 4.12 4.04 4.08 3.91 -10.02 -9.68 -8.86 -7.34 5.82 5.76
Long-Term Debt to NOPAT		 5.14 5.07 4.84 4.38 5.28 -10.86 -10.43 -10.44 -9.08 7.14 7.27
Altman Z-Score		 2.25 2.41 2.30 2.16 1.97 1.13 1.46 1.69 1.72 1.93 1.60
Noncontrolling Interest Sharing Ratio		 0.17% 0.20% 0.18% 0.21% 0.18% 0.25% 0.23% 0.26% 0.24% 0.35% 0.31%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.25 1.42 1.39 1.18 1.43 1.11 1.16 1.24 1.25 1.28 1.21
Quick Ratio		 0.87 1.01 0.94 0.77 1.04 0.78 0.78 0.84 0.91 0.94 0.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4,197 3,131 2,464 5,850 5,943 -9,746 569 1,507 1,963 9,899 11,400
Operating Cash Flow to CapEx		 955.49% 1,068.35% 728.57% 1,389.18% 1,288.48% 997.89% 887.79% 1,725.62% 1,174.34% 751.54% 1,085.04%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.46 0.47 0.47 0.47 0.47 0.49 0.51 0.51 0.50 0.50
Accounts Receivable Turnover		 4.79 4.94 4.72 4.51 4.33 4.44 4.32 4.45 4.46 4.48 4.18
Inventory Turnover		 4.94 4.58 4.75 4.84 4.64 8.89 9.27 8.96 10.48 5.20 5.56
Fixed Asset Turnover		 7.50 7.44 7.33 7.18 6.98 6.99 7.05 7.09 7.01 6.82 6.71
Accounts Payable Turnover		 3.66 3.52 3.60 4.03 3.69 7.38 7.39 8.23 7.97 3.89 3.52
Days Sales Outstanding (DSO)		 76.13 73.90 77.41 80.89 84.37 82.17 84.50 82.06 81.87 81.40 87.37
Days Inventory Outstanding (DIO)		 73.89 79.65 76.83 75.47 78.64 41.06 39.39 40.73 34.84 70.25 65.65
Days Payable Outstanding (DPO)		 99.80 103.83 101.47 90.50 99.05 49.46 49.37 44.36 45.80 93.74 103.64
Cash Conversion Cycle (CCC)		 50.22 49.73 52.77 65.86 63.96 73.77 74.52 78.43 70.91 57.91 49.38
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 61,185 60,447 60,976 58,656 56,613 62,188 62,448 58,534 54,858 55,031 52,726
Invested Capital Turnover		 0.74 0.75 0.74 0.74 0.76 0.74 0.75 0.81 0.87 0.81 0.83
Increase / (Decrease) in Invested Capital		 -2,408 -1,202 -517 -4,149 -4,572 1,741 1,472 -122 -1,755 -7,157 -9,722
Enterprise Value (EV)		 169,192 166,961 155,891 144,239 125,477 154,774 128,358 145,128 151,984 160,085 128,268
Market Capitalization		 139,068 138,338 126,888 114,256 98,294 109,076 82,925 103,736 113,461 122,441 92,978
Book Value per Share		 $14.61 $15.16 $15.22 $13.88 $14.46 $8.13 $8.39 $8.46 $8.05 $8.57 $8.57
Tangible Book Value per Share		 ($12.20) ($10.91) ($9.75) ($10.10) ($9.24) ($18.75) ($16.84) ($15.57) ($14.15) ($13.22) ($12.64)
Total Capital		 70,438 69,716 69,706 66,666 69,257 72,225 69,458 66,952 66,037 67,159 66,674
Total Debt		 39,320 37,830 37,676 37,604 39,772 55,677 52,389 49,752 49,649 49,711 49,185
Total Long-Term Debt		 35,056 35,078 34,656 32,137 36,653 49,487 48,858 48,674 47,603 46,157 44,470
Net Debt		 30,067 28,561 28,946 29,919 27,128 45,640 45,379 41,334 38,470 37,585 35,236
Capital Expenditures (CapEx)		 346 278 259 342 330 284 262 324 378 260 361
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 394 1,484 2,214 1,952 347 -633 503 -1,579 -2,807 -1,515 -3,194
Debt-free Net Working Capital (DFNWC)		 9,647 10,753 10,944 9,637 12,627 9,037 7,156 6,515 8,052 10,267 10,409
Net Working Capital (NWC)		 5,383 8,001 7,924 4,170 9,508 2,847 3,625 5,437 6,006 6,713 5,694
Net Nonoperating Expense (NNE)		 -236 -338 -130 -233 -391 3,904 357 170 132 280 365
Net Nonoperating Obligations (NNO)		 30,067 28,561 28,946 29,594 27,128 45,640 45,379 41,334 38,470 37,583 35,237
Total Depreciation and Amortization (D&A)		 2,521 2,429 2,432 2,435 2,464 2,532 2,596 2,592 1,880 1,012 1,011
Debt-free, Cash-free Net Working Capital to Revenue		 0.85% 3.24% 4.90% 4.34% 0.77% -1.39% 1.08% -3.33% -5.81% -3.18% -6.70%
Debt-free Net Working Capital to Revenue		 20.90% 23.45% 24.22% 21.45% 28.06% 19.85% 15.39% 13.73% 16.67% 21.55% 21.82%
Net Working Capital to Revenue		 11.66% 17.45% 17.54% 9.28% 21.13% 6.25% 7.79% 11.46% 12.43% 14.09% 11.94%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.95 $1.08 $0.99 $0.94 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.21 $0.64
Adjusted Weighted Average Basic Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Adjusted Diluted Earnings per Share		 $0.95 $1.07 $0.99 $0.93 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.20 $0.64
Adjusted Weighted Average Diluted Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.10B 2.10B 2.09B 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B
Normalized Net Operating Profit after Tax (NOPAT)		 1,149 1,929 1,220 1,701 912 -8,005 1,091 1,385 336 2,742 1,678
Normalized NOPAT Margin		 10.08% 17.02% 10.87% 15.51% 7.95% -67.46% 8.94% 11.64% 2.72% 24.48% 13.68%
Pre Tax Income Margin		 16.30% 24.43% 16.56% 19.49% 14.59% -97.06% 10.54% 14.09% 1.42% 26.52% 14.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 73.03% 63.38% 58.82% 56.96% 59.01% -77.59% -73.22% -66.30% -54.44% 90.29% 97.79%
Augmented Payout Ratio		 199.13% 107.74% 110.92% 148.14% 123.12% -157.54% -134.50% -66.30% -54.44% 90.29% 97.79%

Key Financial Trends

Bristol Myers Squibb (NYSE:BMY) has demonstrated a generally positive financial performance over the last four years, with several favorable trends in revenue, profitability, cash flow, and balance sheet strength. Here’s a summary of the key financial observations based on recent quarterly data:

  • Revenue growth: Operating revenues have steadily increased from about $11 billion quarterly in 2022 to over $12 billion per quarter in 2025, indicating consistent top-line growth.
  • Profitability recovery and growth: After a significant net loss in Q1 2024 driven by a one-time charge, net income rebounded strongly with Q2 2025 recording approximately $1.3 billion in net income. Earnings per share have also improved consistently, reaching $0.64 diluted EPS in Q2 2025.
  • Strong operating cash flow: Bristol Myers Squibb generated robust cash from operations, with $3.9 billion in Q2 2025 and generally healthy cash flow through prior quarters, supporting business investments and shareholder returns.
  • Healthy liquidity position: Cash and equivalents have increased to nearly $12.6 billion as of Q2 2025, up from under $9 billion two years ago, providing strong liquidity to fund operations and strategic initiatives.
  • Controlled capital spending: Capital expenditures remain moderate (around $260 million to $360 million quarterly), supporting ongoing business needs without excessive spending.
  • Stable dividends: The company has consistently paid dividends, with a quarterly payout of approximately $0.62 per share in 2025, reflecting a commitment to returning capital to shareholders.
  • Significant acquisition investment: Acquisition spending increased notably in Q2 2024 (~$1.37 billion) and remains a material use of cash, indicating a strategic growth focus but also increasing investment risk.
  • Amortization and non-cash adjustments: Elevated amortization expenses (~$830 million quarterly) and non-cash adjustments reflect intangible asset costs from acquisitions, which while non-cash, may impact future earnings power.
  • Elevated long-term debt: Long-term debt increased from ~$35 billion in 2022 to over $44 billion by mid-2025, raising leverage and interest cost considerations.
  • Q1 2024 one-time net loss impact: The substantial net loss of ~$11.9 billion in Q1 2024, largely due to non-recurring items, significantly impacted annual results and diluted equity returns that period.

Overall, Bristol Myers Squibb has exhibited sustained revenue and profit growth with strong cash flow generation and a healthy balance sheet supporting ongoing operations and shareholder returns. The impactful one-time loss in early 2024 stands out but appears to be an isolated event. Leverage has increased but remains manageable given the company’s cash flows and liquidity. Investors should monitor the company’s acquisition strategy and debt levels as part of the overall investment thesis.

08/08/25 03:19 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Bristol Myers Squibb's Financials

When does Bristol Myers Squibb's financial year end?

According to the most recent income statement we have on file, Bristol Myers Squibb's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bristol Myers Squibb's net income changed over the last 10 years?

Bristol Myers Squibb's net income appears to be on a downward trend, with a most recent value of -$8.93 billion in 2024, falling from $2.03 billion in 2014. The previous period was $8.04 billion in 2023. See where experts think Bristol Myers Squibb is headed by visiting Bristol Myers Squibb's forecast page.

What is Bristol Myers Squibb's operating income?
Bristol Myers Squibb's total operating income in 2024 was -$7.49 billion, based on the following breakdown:
  • Total Gross Profit: $20.96 billion
  • Total Operating Expenses: $28.45 billion
How has Bristol Myers Squibb's revenue changed over the last 10 years?

Over the last 10 years, Bristol Myers Squibb's total revenue changed from $15.88 billion in 2014 to $48.30 billion in 2024, a change of 204.2%.

How much debt does Bristol Myers Squibb have?

Bristol Myers Squibb's total liabilities were at $76.22 billion at the end of 2024, a 16.1% increase from 2023, and a 306.1% increase since 2014.

How much cash does Bristol Myers Squibb have?

In the past 10 years, Bristol Myers Squibb's cash and equivalents has ranged from $2.39 billion in 2015 to $14.55 billion in 2020, and is currently $10.35 billion as of their latest financial filing in 2024.

How has Bristol Myers Squibb's book value per share changed over the last 10 years?

Over the last 10 years, Bristol Myers Squibb's book value per share changed from 8.95 in 2014 to 8.05 in 2024, a change of -10.0%.


Related Companies

This page (NYSE:BMY) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsored
Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsored
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Crypto 101 Media | Sponsored
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsored
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...
Brownstone Research | Sponsored
Critical AI announcement set to ignite AI 2.0
A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...
Timothy Sykes | Sponsored
Trump’s new nightmare
According to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...
Porter & Company | Sponsored